180 Life Sciences Corp., a clinical stage biotechnology company, focuses on developing therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases in the United States. The company product development platforms include fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which has completed phase 2a and phase 2b proof-of-concept clinical trials for early-stage Dupuytren's Contracture; and Synthetic Cannabidiol (CBD) Analogs platform, which are synthetic pharmaceutical grade molecules close or distant analogs of non-psychoactive cannabinoids, such as CBD for the treatment of inflammatory diseases and pain. 180 Life Sciences Corp. is headquartered in Palo Alto, California.
Frequently asked questions
What sector does CannBioRx Life Sciences Corp (ATNFW) operate in?
CannBioRx Life Sciences Corp belongs to the Healthcare sector and operates in the Biotechnology industry.
What is CannBioRx Life Sciences Corp (ATNFW) current stock price?
As of the latest data, CannBioRx Life Sciences Corp stock price is $0.43, with a previous close of $0.46. CannBioRx Life Sciences Corp lost -$0.03 in the last trading session, representing a -6.52% loss.
What is CannBioRx Life Sciences Corp (ATNFW) current market capitalization?
CannBioRx Life Sciences Corp market cap is approximately 250.78 million.
Does CannBioRx Life Sciences Corp (ATNFW) pay dividends?
No. CannBioRx Life Sciences Corp does not pay a dividend.
What is CannBioRx Life Sciences Corp (ATNFW) beta (volatility) score?
CannBioRx Life Sciences Corp has a beta of 0.406, indicating lower volatility than the overall market.
